Other News 2011
BB Biotech AG has chosen the system SDIR-NIS for the transmission of Regulated Information. The system SDIR-NIS is managed by Blt Market Services that belongs to the London Stock Exchange Group, Piazza degli Affari 6, Milano.
Only available in German and French
All proposals put forward by the Board of Directors at the Annual General Meeting of March 19, 2012 were approved by a vast majority of shareholders.
Only available in German or French
On November 30, 2011, BB Biotech AG completed its seventh share buyback program which was initiated on March 21, 2011. During this period a total of 1 640 250 registered shares were bought back through the second trading line.
BB Biotech AG is a major shareholder in the Swiss biotech company Actelion and its Board of Directors has issued a statement explaining its stance prior to Actelion’s upcoming general meeting of shareholders. BB Biotech will conduct itself as in the past, as a critical shareholder demanding good corporate stewardship, but it shall also continue to maintain a constructive relationship with the Management and the Board of Directors of Actelion. Therefore, we intend to support the proposals being put forward by Actelion at its upcoming general meeting.
Annual General Meeting of BB Biotech AG
